[Updated] Team says rapid Angel-investor enlistment is one reason this is a 'W' for region's LifeSciences
Breast cancer target, regulatory progress and further capital raise action likely.
Seed to B-round scenario begins to emerge, with pharmacogenetic testing a driver.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: